title: How accurate is in vitro prediction of carcinogenicity?
abstract: Positive genetic toxicity data suggest carcinogenic hazard, and this can stop a candidate pharmaceutical reaching the clinic. However, during the last decade, it has become clear that many non-carcinogens produce misleading positive results in one or other of the regulatory genotoxicity assays. These doubtful conclusions cost a lot of time and money, as they trigger additional testing of apparently genotoxic candidates, both in vitro and in animals, to discover whether the suggested hazard is genuine. This in turn means that clinical trials can be put on hold. This review describes the current approaches to the 'misleading positive' problem as well as efforts to reduce the use of animals in genotoxicity assessment. The following issues are then addressed: the application of genotoxicity testing screens earlier in development; the search for new or improved in vitro genotoxicity tests; proposed changes to the International Committee on Harmonisation guidance on genotoxicity testing [S2(R1)]. Together, developments in all these areas offer good prospects of a more rapid and cost-effective way to understand genetic toxicity concerns.
authors.affiliation: University of Manchester, Manchester, UK. richard.walmsley@manchester.ac.uk
authors.forename: Richard Maurice
authors.initials: RM
authors.lastname: Walmsley
authors.forename: Nicholas
authors.initials: N
authors.lastname: Billinton
mesh_terms: D000818:Animals; D015197:Carcinogenicity Tests; D002273:Carcinogens; D004249:DNA Damage; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical; D005189:False Positive Reactions; D017408:Guidelines as Topic; D009152:Mutagenicity Tests; D009369:Neoplasms / Q000139:chemically induced
chemical_list: D002273:Carcinogens